

Table 5. Nomogram for Direct Xa Inhibitor in Previous 48 hours and Elevated Baseline Heparin Anti-Xa

Heparin Level by Anti-Xa (IU/mL)	Bolus/Hold	Infusion Rate Change
< 0.1	Bolus 40 units/kg & inform MD (max 10,000 units)	increase by 3 units/kg/hr
0.1 – 0.39	Bolus 20 units/kg & inform MD (max 5,000 units)	increase by 2 units/kg/hr
0.4 – 0.69	None	increase by 1 units/kg/hr
0.7 – 1.0	None	NO CHANGE; Therapeutic Range
1.1 – 1.4	None	decrease by 1 units/kg/hr
1.5 – 1.7	Hold infusion 1 hr	decrease by 2 units/kg/hr
> 1.7	Hold infusion 1½ hr & inform MD	decrease by 3 units/kg/hr

Table 6. Laboratory monitoring for UFH infusion

Lab	Initiation/Titration	Maintenance
Heparin level by anti-Xa	6 hours after initiation or resumption of infusion following a hold 6 hours after any rate change	Once 3 consecutive levels are in target range, then check daily
Hemoglobin	24 hours after initiation	Every other day for up to 14 days
Platelets	24 hours after initiation	Every other day for up to 14 days

Table 7. Transitioning between UFH and other anticoagulants

Gradual to Rapid	Continue current infusion rate
Rapid to Gradual	When next level results titrate with new nomogram
Heparin to Enoxaparin	Stop heparin Administer enoxaparin 2-4 hours later
Heparin to DOAC	Stop heparin Give oral anticoagulant at the same time
Heparin to Fondaparinux	Stop heparin Administer fondaparinux 2-4 hours later

References

1. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;127(4):529-555.
2. Writing Committee M, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2012;126(7):875-910.
3. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e419S-e496S.
4. Whitlock RP, Sun JC, Fries SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e576S-e600S.
5. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130(25):e344-426.
6. Smith AR, Dager WE, Gulseth MP. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review. *Am J Health Syst Pharm*. 2020;77(Suppl 3):S59-S65.
7. Faust AC, Kanyer D, Wittkowsky AK. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. *Am J Health Syst Pharm*. 2016;73(24):2037-2041.
8. Plum MD, Hedrick JN, Hockman R, Bazydlo L, Palkimas S. The Relationship between the Initial Anti-factor Xa Measurement and the Duration of Direct Oral Anticoagulant Influence in Patients Transitioning to Heparin. *Pharmacotherapy*. 2020;40(9):880-888.
9. Levito MN, Coons JC, Verrico MM, et al. A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations. *Ann Pharmacother*. 2021;55(5):618-623.
10. Apixaban (Eliquis[®]) [prescribing information]. Bristol-Myers Squibb Company; Princeton, NJ. 2021.
11. Rivaroxaban (Xarelto[®]) [prescribing information]. Janssen Pharmaceuticals, Inc.; Titusville, NJ. . 2021.
12. Dabigatran (Pradaxa[®]) [prescribing information]. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield, CT. 2021.
13. Enoxaparin (Lovenox[®]) [prescribing information]. Sanofi Aventis US LLC. Bridgewater, NJ. 2020.
14. Fondaparinux [prescribing information]. Zydus Pharmaceutical USA Inc.; Pennington, NJ. . 2020.
15. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383-394.